ADMA Biologics (NASDAQ: ADMA) grants CFO RSUs and $8.81 options
Rhea-AI Filing Summary
ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026. He was granted 85,130 restricted stock units (RSUs) that vest over four years, bringing his unvested RSUs to 143,149, including 58,019 from a December 8, 2025 grant. He also received a stock option for 136,363 shares of common stock at an exercise price of $8.81 per share, vesting 25% after one year and the remainder in substantially equal monthly installments through July 16, 2030, with an expiration date of July 16, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Kohler Terry
Role
CFO and Treasurer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 136,363 | $0.00 | -- |
| Grant/Award | Common Stock | 85,130 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 136,363 shares (Direct);
Common Stock — 143,149 shares (Direct)
Footnotes (1)
- These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer. This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.
Key Figures
RSUs granted July 16, 2026: 85,130 units
Unvested RSUs after grant: 143,149 units
Prior unvested RSUs from Dec. 8, 2025: 58,019 units
+4 more
7 metrics
RSUs granted July 16, 2026
85,130 units
Restricted stock units granted to CFO Terry Kohler on July 16, 2026
Unvested RSUs after grant
143,149 units
Total unvested RSUs held by Terry Kohler as of July 16, 2026
Prior unvested RSUs from Dec. 8, 2025
58,019 units
Unvested RSUs from December 8, 2025 grant included in total holdings
Stock options granted
136,363 shares
Shares underlying stock option granted July 16, 2026 to Terry Kohler
Option exercise price
$8.81 per share
Exercise price of stock option granted July 16, 2026
Option expiration date
July 16, 2036
Expiration date of stock option granted to Terry Kohler
Full option vesting date
July 16, 2030
Date on which stock option becomes fully vested, subject to continued service
Key Terms
restricted stock units, Stock Option (Right to Buy), 2022 Equity Compensation Plan, contingent right to receive one share
4 terms
restricted stock units financial
"These shares represent restricted stock units ("RSUs") that will vest over four years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Transaction in a Stock Option (Right to Buy) with underlying common stock"
2022 Equity Compensation Plan financial
"in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did ADMA (ADMA) CFO Terry Kohler receive on July 16, 2026?
Terry Kohler received 85,130 restricted stock units and a stock option for 136,363 shares on July 16, 2026. The RSUs and options are subject to multi‑year vesting schedules tied to his continued service with ADMA Biologics.
How do Terry Kohler’s new RSUs at ADMA (ADMA) vest over time?
The 85,130 RSUs granted to Terry Kohler vest over four years, subject to his continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of ADMA Biologics common stock upon vesting.
What is the size and exercise price of the new stock option granted to ADMA (ADMA) CFO Terry Kohler?
Kohler received a stock option covering 136,363 shares of ADMA common stock with an exercise price of $8.81 per share. The option was granted on July 16, 2026 and provides the right to buy shares at that price upon vesting.
What is Terry Kohler’s total unvested RSU position in ADMA (ADMA) after this grant?
After the July 16, 2026 grant, Kohler holds 143,149 unvested RSUs. This includes 85,130 RSUs granted on July 16, 2026 and 58,019 RSUs from a December 8, 2025 grant, all subject to continued service-based vesting.
When do Terry Kohler’s new ADMA (ADMA) stock options fully vest and expire?
The stock option becomes fully vested on July 16, 2030, assuming Kohler’s continued service. Vesting occurs 25% after one year, then in substantially equal monthly installments. The option expires July 16, 2036 if not exercised earlier.
Under which plan were the new ADMA (ADMA) awards to Terry Kohler granted?
Both the RSUs and stock option were granted under the ADMA Biologics, Inc. 2022 Equity Compensation Plan. The plan governs vesting conditions and settlement of RSUs into common stock and the terms of stock options awarded to Kohler.